Is KYMR or SABS more undervalued in 2026?

CirclFi compares Kymera Therapeutics, Inc. (KYMR) and SAB Biotherapeutics, Inc. (SABS) using 13 institutional-grade valuation models. KYMR has a Quality of Company score of 7.2/10 while SABS scores 5.0/10.

Which is a better buy — KYMR or SABS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KYMR and SABS valuations compare?

KYMR at $81.46 and SABS at $3.57 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KYMR vs SABS Valuation Comparison 2026 — Intrinsic Value Analysis

KYMR

Biological Products, (No Diagnostic Substances)

Kymera Therapeutics, Inc.

Quality

7.2

out of 10

Value Trap

LOW

Price

$81.46

Last close

Models

12/13

Active

SABS

Biological Products, (No Diagnostic Substances)

SAB Biotherapeutics, Inc.

Quality

5.0

out of 10

Value Trap

WARN

Price

$3.57

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	KYMR Fair Value	KYMR Upside	SABS Fair Value	SABS Upside
Bayesian DCF	Intrinsic	$18.29	-77.6%	$1.27	-64.5%
Earnings Power Value	Intrinsic	$38.43	-54.7%	$6.17	+77.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KYMR vs SABS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KYMR vs SABS — Which Stock Is More Undervalued?

KYMR scores higher with a 7.2/10 quality rating vs SABS's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kymera Therapeutics, Inc. (KYMR) and SAB Biotherapeutics, Inc. (SABS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KYMR currently trades at $81.46 with a QOC of 7.2/10, while SABS trades at $3.57 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).